BM 12.434, a novel compound with vasodilating and beta-adrenoceptor-blocking activities

Area of Science:

• Pharmacology
• Cardiovascular Medicine

Background:

• Beta-adrenoceptor blockers are crucial for managing cardiovascular conditions.
• Metipranolol is a known beta-adrenoceptor blocker.
• Isosorbide-5-mononitrate is used for angina treatment.

Purpose of the Study:

• To compare the cardiovascular effects of BM 12.434 with metipranolol.
• To evaluate the impact of BM 12.434 on peripheral resistance, arterial flow, and venous capacity.
• To assess the effects of a combination therapy including metipranolol and isosorbide-5-mononitrate.

Main Methods:

• Healthy volunteers participated in the study.
• Equi-effective beta-adrenoceptor-blocking doses of BM 12.434 and metipranolol were administered.
• Cardiovascular responses were monitored using non-invasive techniques.

Main Results:

• BM 12.434 demonstrated a lesser increase in peripheral resistance compared to metipranolol.
• BM 12.434 significantly increased arterial flow and venous capacity, unlike metipranolol.
• The combination of isosorbide-5-mononitrate and metipranolol showed a slight increase in venous capacity compared to metipranolol alone.

Conclusions:

• BM 12.434 exhibits beta-adrenoceptor blocking activity.
• Additional vasodilatory effects on arteries and veins position BM 12.434 as a promising agent.
• BM 12.434 holds potential for treating coronary heart disease and arterial hypertension.